T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
901
Sarepta Therapeutics
SRPT
$1.95B
| $66.2M | 0.01% |
735,558
+26,114
| +4% | +$2.23M |
|
902
Quanta Services
PWR
$101B
| $65.9M | 0.01% |
574,643
-251
| -0% | -$28.9K |
|
|
DHR.PRB
903
DELISTED
Danaher Corporation 5.00% Mandatory Convertible Preferred Stock, Series B
DHR.PRB
| $65.7M | 0.01% |
+37,738
| New | +$62.3M |
|
904
Repay Holdings
RPAY
$317M
| $65.2M | 0.01% |
3,571,125
-98,430
| -3% | -$1.93M |
|
905
Patrick Industries
PATK
$2.78B
| $65.1M | 0.01% |
1,210,110
-17,028
| -1% | -$915K |
|
906
James River Group Holdings
JRVR
$200M
| $64.9M | 0.01% |
2,253,930
-459,294
| -17% | -$14.2M |
|
|
HHR
907
DELISTED
HeadHunter Group PLC American Depositary Shares
HHR
| $64.9M | 0.01% |
1,270,149
-35,875
| -3% | -$1.95M |
|
|
CIR
908
DELISTED
CIRCOR International, Inc
CIR
| $64.4M | 0.01% |
2,370,072
+136,293
| +6% | +$4.15M |
|
|
BHVN
909
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $64.2M | 0.01% |
465,977
+41,760
| +10% | +$5.31M |
|
910
Qualys
QLYS
$6.78B
| $64.1M | 0.01% |
466,990
-229
| -0% | -$29.3K |
|
911
IDEAYA Biosciences
IDYA
$3.53B
| $63.9M | 0.01% |
2,701,525
+365,619
| +16% | +$8.49M |
|
912
JELD-WEN Holding
JELD
$170M
| $63.8M | 0.01% |
2,419,143
-144,151
| -6% | -$3.74M |
|
913
Fastenal
FAST
$58.9B
| $63.7M | 0.01% |
1,987,758
-63,714
| -3% | -$1.88M |
|
|
AGNT
914
AGNT Inc
AGNT
$752M
| $63.6M | 0.01% |
1,889,251
+1,734,685
| +1,122% | +$71.5M |
|
915
FormFactor
FORM
$10.3B
| $63.4M | 0.01% |
1,386,941
-4,810
| -0.3% | -$197K |
|
916
Dow Inc
DOW
$21.9B
| $63.3M | 0.01% |
1,116,081
-51,700
| -4% | -$2.95M |
|
|
LL
917
DELISTED
LL Flooring Holdings, Inc.
LL
| $63.3M | 0.01% |
3,706,701
-53,064
| -1% | -$935K |
|
918
SLB Ltd
SLB
$77.3B
| $63.2M | 0.01% |
2,111,045
-50,711
| -2% | -$1.6M |
|
919
eBay
EBAY
$46.5B
| $63.1M | 0.01% |
948,381
-62,875
| -6% | -$4.49M |
|
920
Insperity
NSP
$2.05B
| $63M | 0.01% |
533,430
-4,623
| -0.9% | -$546K |
|
921
Healthcare Realty
HR
$6.58B
| $62.7M | 0.01% |
1,878,984
+17,371
| +0.9% | +$580K |
|
922
Prudential Financial
PRU
$43B
| $62.6M | 0.01% |
578,509
-36,075
| -6% | -$3.92M |
|
923
Visteon
VC
$2.86B
| $62.6M | 0.01% |
563,319
-58,968
| -9% | -$6.55M |
|
924
Lantheus
LNTH
$6.59B
| $62.6M | 0.01% |
2,165,371
-114,540
| -5% | -$3.05M |
|
925
T. Rowe Price
TROW
$23.7B
| $62.5M | 0.01% |
317,959
-13,505
| -4% | -$2.74M |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.